Home > Insider Trading > Filing (0001209191-11-057456)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1466301	Clovis Oncology Inc.	CLVS	Pharmaceutical Preparations (2834)	900475355

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1266569	J Patrick Mahaffy	C/O Clovis Oncology, Inc. 2525 28Th Street, Suite 100 Boulder CO 80301	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-11-21	17,835	$0.00	828,181	No	4	C	Direct
Common Stock	Acquisiton	2011-11-21	17,835	$0.00	846,016	No	4	C	Direct
Common Stock	Acquisiton	2011-11-21	38,605	$0.00	884,621	No	4	C	Direct
Common Stock	Acquisiton	2011-11-21	16,239	$0.00	900,860	No	4	C	Direct
Common Stock	Acquisiton	2011-11-21	39,927	$13.00	940,787	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2011-11-21	51,724	$0.00	17,835	$0.00
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2011-11-21	51,724	$0.00	17,835	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2011-11-21	111,957	$0.00	38,605	$0.00
Common Stock	Convertible Promissory Notes	Disposition	2011-11-21	0	$0.00	16,239	$13.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

The reported securities were convertible at any time, in whole or in part, at the option of the reporting person, had no expiration date, and automatically converted into shares of Common Stock on November 21, 2011, the closing of the Issuer's initial public offering, on a 2.9 for 1 basis.
The outstanding $206,000 principal amount of these 5% convertible promissory notes due May 25, 2012 and all accrued and unpaid interest thereon from and after May 25, 2011 automatically converted into shares of Common Stock on November 21, 2011, the closing of the Issuer's initial public offering, at a conversion price of $13.00, the per share price to the public of the Common Stock sold in the Issuer's initial public offering.